ATNM Financials

Income Statement
MetricQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025
Revenue
0
0
-100.0%
90.0K
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
-100.0%
90.0K
0
0
Operating Expenses
5.9M
-8.0%
6.4M
+10.9%
5.8M
-22.9%
7.5M
-54.9%
16.6M
R&D
4.2M
-2.2%
4.3M
+1.2%
4.2M
-12.9%
4.9M
-36.6%
7.7M
SG&A
1.7M
-19.6%
2.1M
+38.0%
1.5M
-41.5%
2.6M
-70.6%
8.9M
Operating Income
-5903000
+8.0%
-6414000
-12.7%
-5692000
+24.1%
-7503000
+54.9%
-16638000
EBITDA
-5874000
+14.3%
-6856000
-25.0%
-5486000
+24.8%
-7299000
+56.0%
-16591000
Net Income
-5522000
+7.0%
-5940000
-15.8%
-5131000
+25.4%
-6878000
+56.8%
-15938000
EPS (Basic)
$-0.18
+5.3%
$-0.19
-18.8%
$-0.16
+27.3%
$-0.22
+56.9%
$-0.51
EPS (Diluted)
$-0.18
+5.3%
$-0.19
-18.8%
$-0.16
+27.3%
$-0.22
+56.9%
$-0.51
Shares (Diluted)
31.2M
+0.1%
31.2M
+0.0%
31.2M
+0.0%
31.2M
+0.0%
31.2M
Actinium Pharmaceuticals (ATNM) โ€” Financials